Cancer Test Maker, Biotech Firm Prime IPOs Totaling $326M
A maker of cancer diagnostic tests and an early-stage biotechnology firm specializing in retinal diseases have set price ranges on initial public offerings estimated to raise a combined $326 million, joining...To view the full article, register now.
Already a subscriber? Click here to view full article